India\u2019s diabetes challenge is growing fast, and access to modern treatment options matters more than ever. In a new move aimed at improving care, Abbott has partnered with Novo Nordisk India to bring Extensior, a semaglutide-based therapy, to Indian patients. The medicine is based on semaglutide, the same molecule used in Ozempic, and is designed for adults with type 2 diabetes.<\/p>\n
Through this collaboration, Abbott will commercialise Extensior in India, combining Novo Nordisk\u2019s expertise in GLP-1 science with Abbott\u2019s wide reach across the country.<\/p>\n
WHAT THE PARTNERSHIP MEANS<\/p>\n
Under the agreement, Novo Nordisk will develop and manufacture semaglutide, while Abbott will handle its commercial presence in India under the brand name Extensior.<\/p>\n
The aim is simple: help more people with type 2 diabetes access evidence-based treatment options that go beyond basic blood sugar control.<\/p>\n
This collaboration brings together Novo Nordisk\u2019s long-standing work in GLP-1 therapies and Abbott\u2019s strong on-ground presence in India, especially in diabetes medicines, diagnostics and nutrition.<\/p>\n
WHY SEMAGLUTIDE MATTERS<\/p>\n
Extensior is approved as an add-on to diet and exercise for adults with type 2 diabetes. As a GLP-1 receptor agonist, it offers a wide range of benefits for people living with the condition.<\/p>\n
Semaglutide has shown strong HbA1c reduction, weight-loss benefits, and reduced risk of cardiovascular and kidney events in people with type 2 diabetes.<\/p>\n
Its safety and effectiveness are backed by more than 44 clinical trials and over 10 real-world studies across diabetes, obesity, heart, liver and kidney disease.<\/p>\n
Globally, semaglutide has been in use for close to a decade, with over 49 million patient-years of experience across all its products.<\/p>\n
WHAT ABBOTT AND NOVO NORDISK SAY<\/p>\n
Kartik Rajendran, Managing Director, Abbott India Limited, said:
\u201cIndia is facing one of the world\u2019s fastest-growing diabetes burdens, and addressing this challenge requires continuous innovation and strong partnerships.<\/p>\n
The launch of Extensior builds on Abbott\u2019s longstanding focus on holistic diabetes management, from medicines to diagnostics, and from continuous glucose monitoring to diabetes-specific nutrition.\u201d<\/p>\n
Vikrant Shrotriya, Managing Director, Novo Nordisk India, added: \u201cSemaglutide represents one of the most important scientific advances in diabetes care in recent decades.<\/p>\n
Our partnership with Abbott will help make this innovative molecule accessible to a greater number of people living with type 2 diabetes in India.\u201d<\/p>\n
AVAILABILITY IN INDIA<\/p>\n
Extensior will be part of Abbott\u2019s expanding advanced diabetes portfolio and is expected to be available to Indian patients soon.<\/p>\n
The launch is positioned as a step towards wider access to modern diabetes therapies in a country with one of the highest diabetes burdens globally.<\/p>\n
– Ends<\/p>\n
Published By: <\/p>\n
vaishnavi parashar<\/p>\n
Published On: <\/p>\n
Feb 27, 2026 17:48 IST<\/p>\n","protected":false},"excerpt":{"rendered":"India\u2019s diabetes challenge is growing fast, and access to modern treatment options matters more than ever. In a…\n","protected":false},"author":2,"featured_media":26439,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[17034,17037,17029,17032,17036,272,17035,17031,17030,17033],"class_list":{"0":"post-26438","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-abbott-india","9":"tag-diabetes-medicines","10":"tag-diabetes-treatment-india","11":"tag-glp-1-therapy","12":"tag-hba1c-reduction","13":"tag-novo-nordisk","14":"tag-novo-nordisk-india","15":"tag-ozempic-india","16":"tag-semaglutide-india","17":"tag-type-2-diabetes-care"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/26438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=26438"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/26438\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/26439"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=26438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=26438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=26438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}